Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
144
Views
5
CrossRef citations to date
0
Altmetric
Study Protocol

Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)

Motoko Tachihara1 Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe City, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4598-220X
ORCID Icon,
Kayoko Tsujino2 Department of Radiation Oncology, Hyogo Cancer Center, Akashi City, Japan
,
Takeaki Ishihara3 Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe City, Japan
,
Hidetoshi Hayashi4 Department of Medical Oncology, Kindai University, Osakasayama City, Japan
,
Yuki Sato5 Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe City, Japan
,
Takayasu Kurata6 Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata City, JapanORCID Iconhttps://orcid.org/0000-0003-4123-3567
ORCID Icon,
Shunichi Sugawara7 Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai City, Japan
,
Isamu Okamoto8 Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan
,
Shunsuke Teraoka9 Internal Medicine III, Wakayama Medical University, Wakayama, Japan
,
Koichi Azuma10 Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka City, Japan
,
Haruko Daga11 Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan
,
Masafumi Yamaguchi12 Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka City, JapanORCID Iconhttps://orcid.org/0000-0002-5601-4749
ORCID Icon,
Takeshi Kodaira13 Departments of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya City, Aichi, JapanORCID Iconhttps://orcid.org/0000-0002-7075-8488
ORCID Icon,
Miyako Satouchi14 Department of Thoracic Oncology, Hyogo Cancer Center, Akashi City, Japan
,
Mototsugu Shimokawa15 Department of Biostatistics, Yamaguchi University Graduate School of Medicine Yamaguchi, Ube City, Japan
,
Nobuyuki Yamamoto9 Internal Medicine III, Wakayama Medical University, Wakayama, JapanORCID Iconhttps://orcid.org/0000-0002-7342-0853
ORCID Icon,
Kazuhiko Nakagawa4 Department of Medical Oncology, Kindai University, Osakasayama City, Japan
& On behalf of members of the West Japan Oncology Group (WJOG) show all
Pages 9167-9173 | Published online: 14 Dec 2021

References

  • Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. doi:10.1016/j.jtho.2015.09.00926762738
  • Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33:2660–2666. doi:10.1200/JCO.2014.60.013026150444
  • Zenke Y, Tsuboi M, Chiba Y, et al. Effect of second-generation vs third-generation chemotherapy regimens with thoracic radiotherapy on unresectable stage III non-small-cell lung cancer: 10-year follow-up of a WJTOG0105 Phase 3 randomized clinical trial. JAMA Oncol. 2021;18:e210113.
  • Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–1929. doi:10.1056/NEJMoa170993728885881
  • Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non–small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28:3739–3745. doi:10.1200/JCO.2009.24.505020625120
  • Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized Phase III Trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953–962. doi:10.1200/JCO.2015.64.882426811519
  • Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–695. doi:10.1172/JCI6731324382348
  • Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458–5468. doi:10.1158/0008-5472.CAN-14-125825274032
  • Peters S, Felip E, Dafni U, et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic Oncology platform NICOLAS Phase II trial. J Thorac Oncol. 2021;16:78–88. doi:10.1016/j.jtho.2020.10.129
  • Lin SH, Lin Y, Yao L, et al. Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC. J Thorac Oncol. 2020;15:248–257. doi:10.1016/j.jtho.2019.10.02431778797
  • Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer, a nonrandomized controlled trial. JAMA Oncol. 2020;6:848–855. doi:10.1001/jamaoncol.2019.673132077891
  • Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830. doi:10.1016/S0140-6736(18)32409-730955977

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.